Skip to Content

Pharmacological-Robotic Interventions to Promote Functional Recovery in SCI

Objective

The purpose of this study is to learn if training using a walking robotic device (called a "Lokomat") and/or a new oral medication (called "Tizanidine", approved be the FDA) are effective in reducing stiffness in your muscles (called muscle "tone") and in providing functional improvements in your walking capacity.

IRB Protocol Number
STU00010311
Principal Investigator(s)
David Chen
M. Mehdi Mirbagheri
W. Zev Rymer

Clinical Trial Categories

  • Gait Research
  • General Rehabilitation
  • Spinal Cord Injury Research

Compensation

  • Provided
Sponsor(s)
National Institutes of Health (NIH)
Contact
Petra Conaway at 312-238-4524
How to Participate
  • Incomplete Spinal Cord Injury
  • Level of the SCI lesion between C1-T10
  • Spasticity in the lower extremities (increased muscle tone/stiffness)
  • Ability to ambulate overground with assistive devices as needed (at least few steps)

Compensation Provided  

Participants will receive $40 for each testing session. In addition, if participants are assigned for Lokomat training, an additional $15 for each training session attended will be received.